product concentration
Depending on a few products for most revenue.
Exposure · 9 companies
ABBV AbbVie
Exposed“Skyrizi and Rinvoq each generated more than 10% of 2025 total net revenues and together accounted for approximately **42%**.”
- Revenue$61.2BYoY +8.6%
- Net income$4.2BYoY −1.2%
- Revenue$17.4BYoY +10.3%
- Net income$4.2Bvs $186.0M year ago
GOOG Alphabet Inc.
Exposed“Online advertising generated more than 70% of 2025 revenue, making Alphabet vulnerable to changes in advertiser spending, macroeconomic conditions, privacy rules, ad-blocking, and shifts in user behavior.”
- Revenue$402.8BYoY +15.1%
- Net income$132.2BYoY +32.0%
- Revenue$127.6BYoY +24.7%
- Net income$26.5BYoY −24.3%
LLY Eli Lilly and Company
Exposed“Lilly’s revenue is highly concentrated in a small group of products: in 2025, Mounjaro, Zepbound, Verzenio, Trulicity, Taltz, and Jardiance (including Glyxambi, Synjardy, and Trijardy XR) each generated more than $3 billion in direct product and/or collaboration and other revenues and together represented 82% of total revenue.”
- Revenue$65.2BYoY +44.7%
- Net income$20.6BYoY +94.9%
- Revenue$24.4BYoY +38.6%
- Net income$6.5BYoY +15.5%
- Revenue$65.0BYoY +1.3%
- Net income$18.3BYoY +6.6%
- Revenue$18.1BYoY +4.7%
- Net income$5.1BYoY −12.4%
- Revenue$1.3BYoY +29.2%
- Net income$162.0Mvs −$200.0M year ago
PFE Pfizer
Exposed“Pfizer’s sales are concentrated in a limited number of products: 12 products each generated more than $1 billion and together accounted for 65% of 2025 revenue; Eliquis alone represented 13%.”
- Revenue$62.6BYoY −1.6%
- Net income$7.8BYoY −3.2%
- Revenue$16.6BYoY −0.4%
- Net income$3.2BYoY −8.4%
RBLX Roblox Corporation
Exposed“Content is also concentrated: 51% of in-experience hours engaged in December 2025 were in the top 50 experiences.”
- Revenue$4.9BYoY +35.8%
- Net income−$1.1BYoY −13.9%
- Revenue$1.6BYoY +15.6%
- Net income−$227.0MYoY +11.3%
TEL TE Connectivity
Exposed“Approximately 38% of FY2026 net sales came from automotive customers, where downturns, customer work stoppages, sourcing changes, consolidation, and buyer price pressure can reduce demand and profitability.”
- Revenue$19.9BYoY +15.2%
- Net income$3.3BYoY +76.6%
- Revenue$5.2BYoY +13.8%
- Net income$748.0MYoY +17.2%
VRTX Vertex Pharmaceuticals
Exposed“Vertex remains highly dependent on CF revenue and faces clinical, regulatory, reimbursement, manufacturing and supply-chain risks, particularly for cell and gene therapies.”
- Revenue$3.4BYoY +11.8%
- Net income$653.6MYoY −39.6%
No companies have a recent 8-K matching these events.
No companies in the selected roles.